Microbial Biosensors Using Memory Switches for Early IBD Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting inflammatory bowel disease (IBD) flares are invasive, costly, and prone to missed detections due to infrequent and reactive monitoring, particularly with fecal calprotectin assays, leading to unpredictable symptom onset.
Innovation Solution
Development of microbial biosensors, such as engineered E. coli Nissle 1917, that detect calprotectin levels in the gut by using promoters sensitive to zinc deficiency, allowing for early detection of IBD symptoms through fecal markers without direct handling, and incorporating a memory switch for sustained activation and therapeutic gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If fecal calprotectin assays are used for IBD monitoring, then cost and invasiveness are reduced compared to endoscopy or MRI, but detection reliability deteriorates due to borderline results requiring retesting and infrequent administration
Solution Approach 1:
The patent transforms the detection parameter from measuring calprotectin concentration directly to measuring bacterial response to zinc deficiency caused by calprotectin. This changes the detection threshold from absolute concentration values (which have borderline zones) to relative bacterial activation states, eliminating the ambiguity of borderline results and improving detection reliability while maintaining low cost and non-invasiveness
Solution Approach 2:
The patent introduces engineered bacteria as an intermediary between calprotectin and the detection system. Instead of directly measuring calprotectin, the bacteria serve as biological sensors that respond to calprotectin-induced zinc deficiency by activating reporter genes. This intermediary approach converts a chemical measurement problem into a biological response measurement, improving reliability through sustained activation and memory switching mechanisms
2Ease of operation
If fecal calprotectin monitoring is administered infrequently (3× per year), then patient compliance is improved, but the ability to detect symptom onset deteriorates
Solution Approach 1:
The patent implements preliminary detection by using bacteria that activate reporter genes in response to early zinc deficiency signals before clinical symptoms manifest. The memory switch mechanism sustains this early detection signal, allowing patients to detect flares at their onset rather than waiting for symptom development, thereby improving detection capability while maintaining ease of home administration
Solution Approach 2:
The patent achieves continuous monitoring capability through the memory switch mechanism that sustains reporter gene expression even after transient zinc deficiency events. This allows a single administration to provide ongoing detection capability, effectively converting discrete infrequent measurements into continuous monitoring without requiring frequent patient visits, thus maintaining high compliance while improving detection reliability
3Loss of information
If reactive monitoring is used (primarily used reactively to symptom onset), then patient awareness of symptoms is improved, but pre-emptive intervention capability deteriorates
Solution Approach 1:
The patent enables pre-emptive detection by using bacteria that respond to early zinc deficiency signals before clinical symptoms occur. The memory switch sustains this early warning signal, allowing patients to become aware of impending flares days or weeks before symptom onset, providing valuable lead time for pre-emptive intervention while maintaining patient awareness through detectable signals
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables frequent, non-invasive, and proactive monitoring of IBD symptoms, reducing the need for medical oversight and providing timely intervention through detectable fecal changes or therapeutic gene secretion.
Implementation Method 1
using promoters sensitive to zinc deficiency, allowing for early detection of IBD symptoms through fecal markers
Data Source
AI summary
Embodiments of the disclosure relate to methods, compositions, and symptoms for detecting the imminent onset of a symptom of a gut inflammation medical condition and/or treatment thereof. The disclosure concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of gut inflammation, such as with inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual. In various embodiments, the sensor includes a mechanism by which the biosensor is permanently activated to sense inflammation for future detection in the stool.